Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sertraline + aripiprazole
- Development stage
- Phase 4
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sertraline + aripiprazole is a combination therapy being evaluated for the treatment of obsessive-compulsive disorder (OCD). This specific treatment strategy involves the augmentation of the selective serotonin reuptake inhibitor (SSRI) sertraline with the atypical antipsychotic aripiprazole. It is a key intervention arm in the PROCEED (Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD) trial, a phase 2 multi-center study led by the Shanghai Mental Health Center. The combination is intended for patients who do not achieve remission after an initial 12-week course of sertraline monotherapy. Sertraline works by inhibiting the serotonin transporter, while aripiprazole acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. This dual mechanism is hypothesized to enhance therapeutic response in treatment-resistant OCD cases.
- Other names
- aripiprazole augmentation of sertralinesertraline plus aripiprazole
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HRH1 (Histamine H1 Receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on sertraline + aripiprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sertraline + aripiprazole.